-transparent.png){kind=logo}
61 patients with advanced measurable gastric carcinoma were treated with 5-fluorouracil, adriamycin and BCNU (FAB). Of 50 evaluable patients, 48% achieved a response (3 complete and 21 partial responses), and 24% experienced disease stabilization. The median duration of response was 9 months, and median survival of all patients was 7 months. Responding patients survived significantly longer than nonresponders (p less than 0.001). Toxicity was generally mild to moderate, rarely requiring dose reduction or prolongation of treatment intervals. These results indicate that FAB regimen is an active combination in metastatic or locally advanced gastric cancer, and can be used as first-line treatment in patients with this disease.
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
January 1982,
Cancer chemotherapy and pharmacology,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
July 1975,
British journal of diseases of the chest,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
January 1984,
Acta gastroenterologica Latinoamericana,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
July 1977,
British journal of diseases of the chest,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
January 1987,
The Korean journal of internal medicine,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
January 1987,
Oncology,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
January 1976,
British journal of urology,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
January 1976,
Nowotwory,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
June 1982,
Clinical oncology,
M Lopez, and
L Di Lauro, and
P Papaldo, and
E M Conti
August 1968,
Ospedali d'Italia - chirurgia,
